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Introduction Dogs, like humans, suffer from bone disease and
bone injuries that may benefit from mesenchymal stem cell
(MSC)-based therapies. The aim of this study was to investi-
gate the ability of adipose tissue-derived canine MSCs (AT-
MSCs) to differentiate into bone-forming osteoblasts. In
addition, we examined whether supplementation with allo-
geneic bone graft demineralised bone matrix (DBM) also
affected MSC growth and differentiation.
Materials and Methods MSCs were isolated from the inguinal
fat pads of dogs and cultured with either osteogenic media
or control medium for 30 days. These media were supple-
mented with DBM from 3 different dogs; donors A, B and
C. After this treatment period, cell number and growth pat-
terns were examined using phase contrast microscopy and
image analysis, whilst osteogenic differentiation was
assessed by staining for alkaline phosphatase (ALP) activity
and with alizarin red, which detects mineralisation.
Results There was a greater proliferation of cells in control ver-
sus osteogenic conditions. Nodule formation was seen in the
presence of osteogenic medium, but not control medium, albeit
at a low frequency. However, there was a significant increase in
nodule formation when DBM supplementation was added for
two (donor B and donor C) out of three DBM donors. Similarly,
there was a significantly higher frequency of ALP +ve stained
cells and alizarin red stained nodules (confirming mineralisation)
in osteogenic medium when supplemented with donor B DBM
and donor C DBM compared with all other conditions.
Discussion Decreased proliferation, nodule formation,
increased ALP activity and alizarin red-stained mineralisa-
tion of nodules all suggest that the AT MSCs underwent
osteogenic differentiation. However, the evidence of donor
variation in DBM activity requires further study, e.g. to
examine differences in content or release of bone mor-
phogenic proteins. Nonetheless, this study has provided evi-
dence that AT MSCs coupled with DBM have application in
the treatment of bone diseases or injuries in dogs.
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Introduction Tendon injuries can occur due to sports related
incidents, as result of trauma to overuse or during disease or
ageing. Using proteomic techniques tendon protein profiles
could be defined under different conditions. However, little
attempt has been made to identify the optimum protein
extraction technique to increase the coverage of tendon pro-
teome. The aim of this study was to optimise tendon sample
preparations technique for mass spectrometry analysis,
which will be valuable to future tendon research studies.
Materials and Methods Tendon samples were collected from
equine superficial digital extensor tendons (SDFT) that were
between 11–13 years old. The samples were divided in four
parts and subjected to either 4 M guanidine- HCL, 0.1%
Rapigest, a combination of 4M guanidine-HCL and 0.1%
Rapigest or 4M guanidine-HCL followed by 0.1% Rapigest
extraction of the insoluble pellet. Soluble extracts were
reduced, alkylated, trypsin digested and desalted. The prote-
olysed products were identified using LC-MS/MS analysis.
Proteins were identified using PEAK7 (Bioinformatics
Solutions) against the Unihorse database. Progenesis QI
(Waters) was used for label-free quantification.
Results A total of 230 proteins were identified using guani-
dine extraction, 116 proteins with Rapigest extraction, 143
proteins using combination of guanidine and Rapigest
extraction and 206 proteins with guanidine followed by
Rapigest extraction method. The least variability in protein
solubility and in number of identifications was found in the
guanidine followed by Rapigest method. In addition guani-
dine followed by Rapigest method also had the lowest vari-
ability in miss-cleavage compared to the other extraction
methods. Label-free analysis identified significantly more cel-
lular proteins using the guanidine method, whilst the Rapi-
gest alone resulted in significantly more extracellular matrix
proteins such as collagen type I, III, IV and V.
Discussion This study identified the optimum method with
least variability for protein extraction to increase the coverage
of the tendon proteome. The data in this study suggests that
Rapigest mainly functions to increase the extraction of insol-
uble collagen proteins, however it may not be the optimal
method in terms of extracting the cellular proteins. Guanidine
followed by Rapigest method was the most consistent protein
extraction method compared to the other methods.
TSG-6 protects cartilage and bone by modulating the
activities of chondrocytes and osteoclasts: a potential
therapeutic for musculoskeletal disorders
C. M. Milner*, S. P. Drummond*, I. Kanakis*, J. L. Scott*,
G. A. Hassall*, J. M. Thomson*, S. Anand†, A. Price‡, E.
Bartnik§, R. J. van ‘t Hof¶, M. J. Hardman* and A. J. Day*
*Faculty of Life Sciences, University of Manchester, Michael Smith Building,
Oxford Road, Manchester M13 9PT, UK, †Department of Orthopaedics,
Stepping Hill Hospital, Stockport, SK2 7JE, UK, ‡Nuffield Department of
Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of
Oxford, Oxford OX3 7LD, UK, §Sanofi-Aventis Deutschland GmbH,
Industriepark Hoechst, D-65926 Frankfurt, Germany, ¶Institute of Ageing
and Chronic Disease, University of Liverpool, The Apex Building, Liverpool
L7 8TX, UK
Introduction TSG-6 is expressed during inflammation and is
known to protect joint tissues from damage in mouse models of
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rheumatoid arthritis, primarily via its inhibition of neutrophil
extravasation. We have shown recently that the anti-inflamma-
tory activity of TSG-6 is mediated through binding to CXCL8
thereby blocking chemokine-glycosaminoglycan interactions.
Here we investigated the effects of recombinant human (rh)
TSG-6 and its isolated Link module (Link_TSG6) on chondro-
cytes and osteoclasts and evaluated the efficacy of Link_TSG6 in
rodent models of osteoarthritis (OA) and osteoporosis.
Materials and Methods Chondrocytes in 3D pellets were trea-
ted with IL-1/TNFTSG-6 and expression of ADAMTS4,
ADAMTS5 and MMP13 quantified by qPCR. OA cartilage
explants were cultured with IL-1/OSMTSG-6 and proteo-
glycan release measured using the dimethylene blue assay.
The rat ACLTpMx model of surgically-induced OA was
treated with Link_TSG6; joint damage was evaluated by
macroscopy/histology after 4 weeks and pain was assessed
by tactile allodynia. Human or murine osteoclasts were cul-
tured on dentine with M-CSF/RANKLLink_TSG6 and
lacunar resorption and F-actin ring formation quantified.
Ovariectomised (OVX) mice were treated with Link_TSG6
for 8 weeks; effects on bone turnover were assessed by CT
and histomorphometry of long bones.
Results Link_TSG6 was more potent than rhTSG-6 at sup-
pressing IL-1- and TNF-induced expression of ADAMTS4,
ADAMTS5 and MMP13 in human chondrocytes; i.e. the
aggrecanase and collagenase enzymes responsible for carti-
lage degradation in OA. Link_TSG6 also significantly
reduced proteoglycan loss from human OA cartilage
explants and reduced cartilage damage and pain in the rat
ACLTpMx model. in vitro assays showed that Link_TSG6
treatment inhibited osteoclast-mediated resorption via
potent suppression of F-actin ring formation, thereby
impairing attachment of active osteoclasts to the bone
matrix. In Link_TSG6-treated OVX mice trabecular bone
loss was significantly supressed, with the number and activ-
ity of osteoclasts reduced at the bone surface. Importantly
there was no evidence of impaired bone formation.
Discussion The chondroprotective, anti-resorptive and anti-
inflammatory properties of Link_TSG6 make it a unique tar-
get for development as a biological therapy for muscu-
loskeletal disorders. We are now investigating the
mechanism of Link_TSG6 action in cartilage and bone and
whether its activities are mediated through modulation of
cell-matrix interactions.
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Introduction Lowering oxygen from atmospheric (hyperoxia)
to the physiological level (physioxia) of articular cartilage
promotes mesenchymal stem cell (MSC) chondrogenesis.
However, the literature is equivocal regarding the benefits of
physioxic culture on preventing hypertrophy of MSC-
derived chondrocytes. Articular cartilage progenitors (ACPs)
undergo chondrogenic differentiation with reduced hypertro-
phy marker expression in hyperoxia but have not been stud-
ied in physioxia. This study sought to delineate the effects
of physioxic culture on both cell types undergoing chondro-
genesis.
Materials and Methods MSCs were isolated from human bone
marrow aspirates, and ACP clones were isolated from
healthy human cartilage. Cells were differentiated in pellet
culture in physioxia (2% O2) or hyperoxia (20% O2) over
fourteen days. Chondrogenesis was characterized by bio-
chemical assays and gene and protein expression analysis.
Results MSC preparations and ACP clones of high intrinsic
chondrogenicity (termed high-GAG) produced abundant
matrix in hyperoxia and physioxia. Poorly chondrogenic cells
(low-GAG) demonstrated a significant fold-change matrix
increase in physioxia. Both high- and low-GAG groups MSCs
and ACPs significantly upregulated chondrogenic genes; how-
ever, only high-GAG groups had a concomitant decrease in
hypertrophy-related genes. In physioxia, high-GAG MSCs
and ACPs produced comparable type II but less type I colla-
gen than those in hyperoxia. Type X collagen was detectable
in some ACP pellets in hyperoxia but undetectable in physiox-
ia. In contrast, type X collagen was detectable in all MSC
preparations in hyperoxia and physioxia.
Discussion Physioxia significantly enhanced the chondrogenic
potential of both ACPs and MSCs compared with hyperox-
ia, but the magnitude of response corresponded with intrin-
sic chondrogenicity that varied between donors and clones.
Discrepancies reported in the literature regarding MSC
hypertrophy in physioxia may be explained by the use of
low numbers of preparations of variable chondrogenicity.
Physioxic differentiation of MSCs of high chondrogenicity
significantly decreased hypertrophy related genes but still
produced the hypertrophic marker protein, type X collagen.
Highly chondrogenic ACPs had significantly lower hyper-
trophic gene levels, while type X collagen protein was below
detectable levels in physioxia, emphasizing the potential
advantage of these cells. Our work suggests that individual
stem cell populations ought to be characterized prior to fur-
ther experiments because of the potential influence of chon-
drogenicity on results and conclusions.
LaNt a31, a LAMA3 gene derived new protein, co-
distributes with laminin in the extracellular matrix and
induces early hemidesmosome maturation in corneal
epithelial cells
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Introduction LaNt a31 (laminin N-terminal a31), a product
of alternative splicing from the laminin a3 encoding gene
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